Bortero Use In Pregnancy & Lactation





Full Prescribing Info
Use In Pregnancy & Lactation
Pregnancy: Pregnancy Category D.
Advise women of childbearing potential to avoid becoming pregnant while being treated with bortezomib. There are no adequate and well-controlled studies in pregnant women. It is not known if bortezomib crosses the human placenta. The molecular weight (approximately 384), long elimination half-life, moderate plasma protein binding, and lack of rapid metabolism all suggest that the drug will cross to the embryo and/or fetus. If bortezomib is used during pregnancy, or if the patients becomes pregnant while receiving this drug, apprise the patient of the potential hazard to the fetus.
Lactation: It is not known whether bortezomib is excreted in human milk. Bortezomib's long elimination half-life, low molecular weight, and moderate protein binding suggest that it would be excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in breast-feeding infants from bortezomib, decide whether to discontinue breast-feeding or the drug, taking into account the importance of the drug to the mother.
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in